Skip to main content

Non-diabetic Overweight or Obese

4
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
2 programs
2
BGM0504Phase 1
Experimental: 10 mg BGM0504 10 milligramsPhase 1
BrightGene
BrightGeneChina - Suzhou
2 programs
2
BGM0504Phase 11 trial
Experimental: 10 mg BGM0504 10 milligramsPhase 11 trial
Active Trials
NCT07166081Recruiting80Est. May 2026
NCT06714955Completed30Est. Mar 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
BrightGeneBGM0504
BrightGeneExperimental: 10 mg BGM0504 10 milligrams

Clinical Trials (2)

Total enrollment: 110 patients across 2 trials

NCT07166081BrightGeneBGM0504

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

Start: Aug 2025Est. completion: May 202680 patients
Phase 1Recruiting
NCT06714955BrightGeneExperimental: 10 mg BGM0504 10 milligrams

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

Start: Oct 2024Est. completion: Mar 202530 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 110 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.